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RESEARCH ARTICLE
Melanopsin Retinal Ganglion Cell Loss
in Alzheimer Disease
Chiara La Morgia, MD, PhD,1,2 Fred N. Ross-Cisneros, BA,3
Yosef Koronyo, MSc, LLB,4 Jens Hannibal, MD, PhD., DmSc.,5
Roberto Gallassi, MD,1,2 Gaetano Cantalupo, MD,6 Luisa Sambati, MD, PhD,1,2
Billy X. Pan, MD,7 Kevin R. Tozer, MD,7 Piero Barboni, MD,8
Federica Provini, MD, PhD,1,2 Pietro Avanzini, PhD,9 Michele Carbonelli, MD,1
Annalisa Pelosi, PhD,9 Helena Chui, MD,10 Rocco Liguori, MD,1,2
Agostino Baruzzi, MD,1,2 Maya Koronyo-Hamaoui, PhD,4,11
Alfredo A. Sadun, MD, PhD,3,12 and Valerio Carelli, MD, PhD1,2
Objective: Melanopsin retinal ganglion cells (mRGCs) are photoreceptors driving circadian photoentrainment, and
circadian dysfunction characterizes Alzheimer disease (AD). We investigated mRGCs in AD, hypothesizing that they
contribute to circadian dysfunction.
Methods: We assessed retinal nerve fiber layer (RNFL) thickness by optical coherence tomography (OCT) in 21 mild-
moderate AD patients, and in a subgroup of 16 we evaluated rest–activity circadian rhythm by actigraphy. We stud-
ied postmortem mRGCs by immunohistochemistry in retinas, and axons in optic nerve cross-sections of 14 neuropa-
thologically confirmed AD patients. We coimmunostained for retinal amyloid b (Ab) deposition and melanopsin to
locate mRGCs. All AD cohorts were compared with age-matched controls.
Results: We demonstrated an age-related optic neuropathy in AD by OCT, with a significant reduction of RNFL
thickness (p5 0.038), more evident in the superior quadrant (p5 0.006). Axonal loss was confirmed in postmortem
AD optic nerves. Abnormal circadian function characterized only a subgroup of AD patients. Sleep efficiency was sig-
nificantly reduced in AD patients (p5 0.001). We also found a significant loss of mRGCs in postmortem AD retinal
specimens (p5 0.003) across all ages and abnormal mRGC dendritic morphology and size (p5 0.003). In flat-
mounted AD retinas, Ab accumulation was remarkably evident inside and around mRGCs.
Interpretation: We show variable degrees of rest–activity circadian dysfunction in AD patients. We also demonstrate
age-related loss of optic nerve axons and specifically mRGC loss and pathology in postmortem AD retinal specimens,
associated with Ab deposition. These results all support the concept that mRGC degeneration is a contributor to cir-
cadian rhythm dysfunction in AD.
ANN NEUROL 2015;00:000–000
Alzheimer disease (AD) is the most common age-related dementia, characterized by accumulation in
the brain of amyloid-b protein (Ab) plaques and aggre-
gates of hyperphosphorylated tau as neurofibrillary tan-
gles.1 Previous studies have shown circadian dysfunction
of rest–activity, melatonin, and temperature rhythms in
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AD patients.2 In particular, actigraphic studies demon-
strated an increased intradaily variability, and reduced
interdaily stability and relative amplitude of the rest–
activity rhythm in AD.3,4 Moreover, in AD patients there
has been observed neuronal loss in the suprachiasmatic
nucleus (SCN), the circadian pacemaker.5–7 These abnor-
malities, which do not correlate tightly with severity of
dementia, may be ameliorated by light therapy.8
Postmortem studies in AD, besides the well-known
occurrence of neurodegeneration in the brain, also high-
lighted retinal and optic nerve tissue pathology.9–11 In
vivo studies with optical coherence tomography (OCT)
corroborated these findings, showing a reduction of the
retinal nerve fiber layer (RNFL) thickness in AD
patients.12–20 Accumulation of Ab in the retina of AD
patients has also been reported in a few studies. The
original study by Koronyo-Hamaoui et al21 identified Ab
pathology in postmortem retinas of definite and early
stage AD patients. They demonstrated various types of
deposits, including diffuse, immature, and mature pla-
ques, those including Ab1–40 and Ab1–42 species, and
those associated with lipid deposits.21 Elevated Ab1–42
levels and Ab deposits were also found by 2 other inde-
pendent groups in AD patients’ retina22,23 and in various
transgenic rodent models of AD.21–27 Thus, there is mul-
tiple evidence that the neuroretina is affected by the
pathological process of AD.
In the past decade a second light-detecting system
has been identified in the mammalian eye mediating
non–image-forming functions, such as photoentrainment
of circadian rhythms, regulation of pupil size, sleep, alert-
ness, and pineal melatonin synthesis.28–30 These cells rep-
resent a subpopulation (about 1–2%) of retinal ganglion
cells (RGCs) that are intrinsically photosensitive due to
the expression of the photopigment melanopsin
(mRGCs).31 The mRGCs send information on ambient
light to the brain via a monosynaptic neuronal pathway,
known as the retinohypothalamic tract,32 projecting to
the SCN of the hypothalamus.33,34 Loss of mRGCs has
been described with aging35,36 and in some ocular dis-
eases, such as glaucoma,37 and has been suggested to
contribute to circadian dysfunction in these conditions.38
These observations prompted us to hypothesize that
mRGC loss may contribute to circadian dysfunction in
AD. Thus, we studied AD patients assessing the integrity
of the optic nerve by OCT and rest–activity circadian
rhythms by actigraphic recordings. We also objectively
evaluated the RGCs and mRGCs by postmortem histo-
logical analyses in tissue samples from AD patients and
age-matched controls, including retinal immunohisto-
chemistry (IHC) for Ab and Ab–melanopsin costaining
for mRGCs.
Subjects and Methods
OCT Evaluation of Retinal Nerve Fiber Layer
Thickness in AD Patients and Controls
All participants gave their informed consent to this study, which
was approved by the internal review board at the University of
Bologna (Independent Ethics Committee, Local Health Author-
ity of Bologna, Protocol #656/CE).
We included patients with a diagnosis of AD according
to National Institute of Neurological and Communication Dis-
orders–Alzheimer’s Disease and Related Disorders Association
criteria,39 at mild–moderate stage (Mini-Mental State Examina-
tion [MMSE]> 11).40 Absence of cognitive dysfunction was
ascertained in controls.
Exclusion criteria were: (1) spherical or cylindrical refrac-
tive errors higher than 3 or 2 diopters, respectively; and (2)
posterior pole ocular pathology such as age-related macular
degeneration and optic neuropathies, including open-angle high
intraocular pressure glaucoma.
Overall, in vivo ocular studies were performed in 21 AD
patients (age5 71.26 10.5 years, range5 51–84; 11 males) and
74 controls (age5 69.16 8.1 years, range5 52–85 years; 31
males). All subjects underwent RNFL thickness measurements by
OCT (StratusOCT, software version 4.0.1; Carl Zeiss Meditec,
Dublin, CA) with the 3.4 acquisition protocol.41 We retrieved
the average RNFL thickness (360 8 measure), as well as temporal
(316–45 8 unit circle), superior (46–135 8), nasal (136–225 8),
and inferior quadrant thickness (226–315 8). At the beginning of
the examination, lenses were adjusted for the patients’ refractive
errors. Polarization was optimized to maximize the reflective sig-
nal, and the best centration of the scan with respect to the optic
disk was used. For the statistical analysis, 1 eye was randomly
chosen, after verification that there was no statistical difference
between the 2 eyes, as previously reported.41
Average and single sector RNFL thickness values were
used for comparisons between AD patients and controls, and
for correlation with clinical data (see Statistical Analysis).
Actigraphic Evaluation of Rest–Activity
Circadian Rhythm in AD Patients and Controls
In a subgroup of AD patients and controls, belonging to the
same cohorts investigated by OCT, we measured spontaneous
motor activity by a wrist actigraph (Actigraph Mini Motionlog-
ger; Ambulatory Monitoring, Ardsley, NY) worn on the nondo-
minant wrist for 7 days. We also evaluated the occurrence of
sleep disturbances with the following self-administered ques-
tionnaires: Epworth Sleepiness Scale (ESS), Pittsburgh Sleep
Quality Index (PSQI), and Berlin Questionnaire.
Overall, 16 AD patients (age5 70.256 10.2 years,
range5 52–84 years; 8 males) and 10 controls (age5 65.86
7.5 years, range5 54–80 years; 5 males) were studied. AW2
software (Ambulatory Monitoring) was used to analyze the data
collected. This software allowed retrieving the total sleep time
(TST; minutes of rest activity during the night period) and
sleep efficiency (SE; sleep time divided by the time in bed mul-
tiplied by 100). Each participant also completed a sleep diary
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over the 7 days of actigraphic monitoring indicating bed/rise
time, time to sleep onset, and eventual daytime naps.
Actigraphic data were inspected to detect the correspon-
dence with the sleep diary and possible artifacts (low activity due
to the actigraph removal). Each single artifactual epoch was
marked as a “bad” epoch. Furthermore, to allow the comparison
between subjects, all the recordings were aligned with the starting
time at 12:00 AM. Given that 5 subjects wore the actigraph for <7
days, to adequately compare subjects, 120 consecutive hours (5
days) of recordings were considered for subsequent analysis. Data
were then exported to MATLAB (MathWorks, Natick, MA), and
the mean of each hour was computed as the mean of the “good”
epochs. If consecutive bad epochs occupied an entire hour, these
periods were treated as missing data and the hourly mean was cal-
culated as the weighted mean of the pre- and postactivity counts.
Nonparametric methods were applied for the analysis of
circadian measurements.42,43 We thus calculated the interdaily
stability (IS; an index ranging from 0 to 1 reflecting the
strength of the rhythm to supposedly stable environmental zeit-
gebers), the intradaily variability (IV; an index ranging from 0
to 2 measuring the frequency and extent of transitions between
rest and activity), and the relative amplitude (RA; the normal-
ized difference between the most active 10-hour period [M10]
of the rest–activity rhythm and the least active 5-hour period
[L5] in the average 24-hour pattern).
Circadian (IS, IV, RA, M10, and L5) and sleep (TST and
SE) parameters were used for comparisons between AD patients
and controls, and correlation with clinical data (see Statistical
Analysis).
Postmortem Studies of Retinas and Optic
Nerves in AD Patients and Controls
Postmortem control eyes were collected both from the eye tis-
sue bank Lions VisionGift (Portland, OR) and the Alzheimer’s
Disease Research Center (ADRC) Neuropathology Core at the
University of Southern California (USC; Los Angeles, CA).
Postmortem AD eyes were obtained from the ADRC at USC.
Clinical charts of controls and AD patients were reviewed.
Overall, we collected and studied 17 neuropathologically
confirmed AD cases (age5 80.66 13.8 years, range5 51–98
years; 10 males) and 13 age-matched controls (age5
77.86 16.1, range5 54–105; 9 males). The inclusion criteria
for AD cases were a neuropathological diagnosis of high-
likelihood AD according to National Institute on Aging–Reagan
Institute criteria,44 frequent neuritic plaques according to modi-
fied Consortium to Establish a Registry for Alzheimer’s Disease
criteria,45 and Braak stage V or VI,46 based on the neuropatho-
logical reports (Dr C. Miller, ADRC at USC). Exclusion crite-
ria were the presence of significant posterior pole ocular
pathology such as age-related macular degeneration and optic
neuropathies including glaucoma, ischemic optic neuropathy,
and other significant ocular pathology such as diabetic retinopa-
thy. Moreover, exclusion criteria for controls provided by the
eye tissue banks were the presence of neurological and psychiat-
ric disorders, human immunodeficiency virus infection, alcohol
abuse, and diabetes.
All postmortem tissues were immersion-fixed in neutral
buffered formalin. Eyes and optic nerves were oriented for
superior and temporal zones with tissue ink. The eyes were dis-
sected at the horizontal meridian producing 2 calottes each con-
taining the nasal and temporal retina at the level horizontally
bisecting the papillomacular bundle. A ribbon of tissue from
the superior half was embedded into paraffin and serially sec-
tioned at 5 lm. Sections were immunostained for melanopsin
(rabbit antihuman melanopsin polyclonal antibody, code No.
5J68, characterized in detail by Hannibal et al47,48 using an
indirect immunoperoxidase technique with diaminobenzidine
(DAB) as the substrate/chromogen.36 The C-terminal antihu-
man melanopsin antibody was raised in-house in a rabbit
against a fusion protein representing the C-terminal part of
human melanopsin (amino acid sequence of the fusion protein
was MRGSHHHHHHGMASMTGGQQMGRDLYDDDDK
DHPFTHPKYRVAIAQHLPCLGVLLGVSRRHSRPYPSYRSTH
RSTLISHTSNLSWISIRRRQESLGSESEVGWTHMEAAAVWG
AAQQANGRSLYQGLEDLEAKAPPRPQGHEAETPGKTKGLI
PSQDPRM) as previously detailed.47,48 The C-terminal antime-
lanopsin antibody (diluted 1:10,000) was characterized by preab-
sorption of the antibody with the immunization material
dialyzed against phosphate-buffered saline (PBS) with 0.1%
Tween, which abolished all staining, as previously reported.47,48
The rabbit antihuman melanopsin antiserum recognized human
and monkey but not rodent melanopsin. An N-terminal antime-
lanopsin antibody (a kind gift from Dr K.-W. Yau, Johns Hop-
kins University; code hNA diluted 1:500), which was raised in
rabbit against a peptide consisting of 19 amino acid residues,
MNPPSGPRVPPSPTQEPSC, from the N-terminus of the con-
ceptually translated human melanopsin protein (National Center
for Biotechnology Information accession number AAF24978),49
was used to verify that the C– and N-terminal melanopsin anti-
bodies stained identically. Identical staining was obtained on the
same section using retinal sections from either human (unpub-
lished data) or monkey.48
We analyzed 1 eye from each postmortem subject for
mRGC number and morphology and its optic nerve for total
axonal counts. Melanopsin RGCs were identified and manually
counted and further confirmed and photographed at 31,000
magnification. Counting has been performed based on a modi-
fied version of a previously published protocol.36 Briefly, we
counted only immunoreactive mRGCs containing a prominent
nucleus (central profile counting).50 Furthermore, to avoid
counting the same nucleus twice, we applied a “section separa-
tion” approach by counting central profiles for every 5th sec-
tion.50 Central profile counting, coupled with section
separation, may minimize counting errors,50 but does not elimi-
nate the problem of overcounting large objects embedded in
thin sections.51,52 Thus, we used Abercrombie’s equation to cor-
rect the immunoreactive mRGC number, multiplying the cen-
tral profile counts by T/(T1 h), where T is the section
thickness (5 mm) and h is the mean diameter of the nucleus.52
To obtain the mean diameter of the mRGC nuclei, we
first performed a simple random sampling of 2 immunoreactive
mRGCs from the 5 immunostained slides available for each
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patient in the control and AD groups. Two of the 5 numbered
slides were selected randomly, and the first cell identified with a
nucleus was chosen for measurement. There were 13 controls
and 14 AD patients. Thus, we measured 26 nuclei in the con-
trol group and 28 nuclei in the AD group at a magnification of
31,000 on a bright-field microscope. The shortest diameter of
mRGC nuclei was considered for calculations.
To perform the measurements of the nuclei from immuno-
reactive mRGCs, we used a SPOT Imaging Solutions software
program, version 4.6 (Diagnostic Instruments, Sterling Heights,
MI), which was calibrated at 31,000 with a Bausch1Lomb
(Rochester, NY) stage micrometer. The mRGC nuclei were
observed on an Axioskop microscope Carl Zeiss Microscopy
LLC, Thornwood, NY, USA and photographed with a SPOT
RTke digital camera, and the images were saved on a computer.
Finally, mRGC density was obtained dividing the Aber-
crombie’s corrected number of mRGCs by the retinal surface
sampled (retinal length3 section thickness).
We computed separately mRGCs located in the inner
nuclear layer (INL) and in the ganglion cell layer (GCL), and
their ratio was calculated to assess the difference in distribution
across groups.
Optic nerves were dissected into cross-sectional profiles
3mm posterior to the globe, postfixed in 3% phosphate-buffered
glutaraldehyde, processed, embedded into plastic blocks, and cut
on an ultramicrotome at 1mm. Tissue sections were placed on
glass slides with a drop of water, dried using a hot plate, cooled,
then stained with para-phenylenediamine (PPD) to label the
myelin ring of the entire population of RGC axons (including
mRGCs). Axons were manually counted on images acquired at
31,000.36 For total axon counts, each nerve cross-section was
partitioned into 4 regions (temporal, nasal, superior, inferior). All
light microscopy (LM) photos of eyes (retinas) and nerves (axons)
were acquired with a Spot II digital camera (Diagnostic Instru-
ments) and saved on a computer.
To grade the severity of brain pathology of AD patients,
we used the published ABC score.53 However, we were able to
compute only the B and the C subscores using the silver stain
for the detection of neurofibrillary tangles (B) and the thiofla-
vin stain for the detection of neuritic plaques (C). The brain
regions analyzed were: hippocampus CA-1 (uncus and lateral
geniculate body), entorhinal cortex, middle frontal, superior/
middle temporal, inferior parietal, primary visual, and visual
associative cortex.
For each subject, we retrieved the density and total num-
ber of mRGCs and the total axon number in optic nerve cross-
sections. These data were used for comparisons between AD
patients and controls, and for correlation with clinical and neu-
ropathological data (see Statistical Analysis).
Morphological Analysis of mRGCs in Flat-
Mounted Retinal Preparations from AD Patients
and Controls
Flat-mounted retinas from 3 controls and 4 age-matched AD
patients, all belonging to the same postmortem cohort, were
treated by antigen retrieval solution (ChemMate; Dako, Car-
pinteria, CA; code No. S2367 in distilled water, pH 9) at 80 8C
for 11=2 to 2 hours before processing for IHC using the antime-
lanopsin antibody (code No. 5J68). IHC detection for mela-
nopsin on flat-mounted retinas was performed as previously
described.47,48 Briefly, after incubation of the primary antibod-
ies for 72 to 84 hours at 4 8C (diluted 1:10,000), melanopsin
was visualized using the Dako Envision kit (code No. K4002,
diluted 1:2) and tyramide-conjugated Alexa 488 (Molecular
Probes, Eugene, OR, USA). Images were obtained using an
iMIC confocal microscope (FEI, Till Photonics, Munich, Ger-
many) equipped with appropriate filter settings for detecting
40,6-diamidino-2-phenylindole (DAPI) and CY2/Alexa 488. For
a more detailed visualization of the melanopsin immunoreactive
network of outer and inner stratifying dendritic processes, Z-
stacks with a focal depth of 30 to 40lm were generated and
the Z-stacks of images were stitched using the LA-stitch module
of Fiji/ImageJ, version 1.47n, 64 bit. Images for 3-dimensional
(3D) analysis were obtained by the spinning disk confocal part
of the microscope. Z-stacks of typically 60 to 70 images sepa-
rated at the Z-level by 0.5 mm were deconvoluted in AutoQuant
X, version 3.02 (Media Cybernetics, Rockville, MD, USA), and
the localization of dendritic processes and cell bodies was fur-
ther analyzed by IMARIS, version 7.6.4 (Bitplane Scientific
Software, Zurich, Switzerland) using the filament tracer mod-
ule.48 After deconvolution, an autoNetwork was created for
each cell analyzed. Thereafter, the lowest (L) and highest (H)
values of dendritic diameters were defined (L5 0.323mm,
H5 16.15 mm). We identified dendrites belonging to the ana-
lyzed cells by manual tracer, the measures obtained were
exported into a spreadsheet, and values from each cell were
computed as a mean value.
Ab Immunohistochemistry and Ab-Melanopsin
Colabeling for mRGCs in Flat-Mounted Retinas
from AD Patients and Controls
Flat-mounted retinas from 5 controls and 5 age-matched AD
cases, all belonging to the same postmortem cohort, were
washed in 31 PBS and treated with target retrieval solution
(S1699, Dako), pH 6.1, at 96 8C for 1 hour. Tissues were
washed in 31 PBS, treated with 3% hydrogen peroxide for 12
minutes, and washed again in 31 PBS. Thereafter, retinas were
immunostained using the Vectastain ABC kit (PK-610; Vector
Laboratories, Burlingame, CA); first treated with blocking solu-
tion and permeabilized with 0.1% Triton X-100 for 30 minutes
at room temperature. Tissues were then incubated with primary
anti-Ab monoclonal antibodies (6E10, recognizing the 1-16aa
N-terminal or 12F4, recognizing the 42 aa C-terminal) diluted
1:100 in PBS containing 10% permeabilization/blocking solu-
tion for 72 hours at 4 8C. Ab immunoreactivity was detected
by standard immunoperoxidase methodology using the
DAB1 Substrate Chromogen System (K3467, Dako). Bright-
field images were acquired using a Axio Imager Z1 fluorescence
microscope equipped with ApoTome (Carl Zeiss Microimag-
ing), with an AxioCam HRc camera. Images were repeatedly
captured at several focal planes in the same area of the retinas
(superior–temporal quadrant). Controls were processed using
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the same protocol with the omission of the primary antibody
to assess nonspecific labeling.
For fluorescent costaining of melanopsin and Ab antibod-
ies, on the same flat-mount retina tissues that were previously
stained with horseradish peroxidase, the antibodies from the
first enzymatic staining were eluted with glycine sodium
dodecyl sulfate pH 2 buffer for 45 minutes on a platform
shaker in an incubator at 50 8C. Next, the tissues were washed
extensively in PBS (see details in Pirici et al54 and treated with
antigen retrieval solution, as described above. Tissues were then
washed in PBS and blocked for 1 hour with blocking serum
containing 20% donkey serum and 0.1% Triton X-100 (Sigma-
Aldrich, Saint Louis, MO). Tissues were then stained for 72
hours at 4 8C with combinations of the primary antibodies in
PBS with 2% blocking solution: mouse antihuman Ab mono-
clonal antibody, clone 6E10 (1:100; Covance, Emeryville, CA)
recognizing the amino acid 1-16, and the rabbit antihuman
melanopsin antibody (code No. 5J58; 1:2,000). Secondary pol-
yclonal antibodies donkey antimouse, and antirabbit (1:200;
Jackson ImmunoResearch Laboratories, West Grove, PA) conju-
gated to Cy-3, Cy-5, or DyLight 649, were incubated for 1
hour at 37 8C. Subsequently, the tissues were washed in PBS
and mounted with Prolong mounting media containing DAPI
(Thermo-Fisher Scientific/Molecular Probes, Grand Island,
NY). Microscopic analysis was performed by ApoTome
equipped Carl Zeiss Z1 fluorescence microscope.
Statistical Analysis
Normal distribution of data was verified by Kolmogorov–Smir-
nov test.
Comparisons between groups for OCT, actigraphic, and
postmortem data were computed by means of analysis of covar-
iance (ANCOVA) with age and gender as covariates. When
appropriate, a group3 age interaction was evaluated in the
ANCOVA model. Significance was assumed for p< 0.05. Cor-
rections for multiple comparisons were applied with the Bonfer-
roni method. The adjusted critical p value is reported in the
legends of Tables 1 and 2. We also calculated for each compari-
son the minimum detectable effect size assuming an 80%
power and a5 0.05 (dES80%)
55 and compared it to the
observed effect size (expressed as Cohen f ).
For in vivo studies, bivariate correlation analysis between
experimental measurements (OCT or actigraphic data) and clin-
ical data (age, age at onset, disease duration, and MMSE) was
performed using Pearson coefficient. We also evaluated the
interaction between age and disease severity by means of an
age3 disease severity interaction model (general linear model).
For postmortem studies, bivariate correlation analysis
between histological (mRGC density, axonal counts, Braak
score, severity of brain pathology) and clinical data (age, disease
duration, MMSE score) was performed using Pearson coeffi-
cient. We also calculated the ratio of mRGCs to total RGCs.
To do this, given the very different order of magnitude of the
values for mRGC and RGC counts, we normalized (transform-
ing into T scores) both axonal and mRGC counts. We thus
compared the obtained ratio (T-score-mRGC/T-score-RGC5
mRGC/RGC ratio) between AD and controls by means of
ANCOVA (with age and gender as covariates).
Statistical analysis was performed using Statistical Package
for Social Sciences (version 22.0; IBM, Armonk, NY).
Results
OCT Evaluation Demonstrated Age-Dependent
Loss of Retinal Nerve Fibers in AD Patients and
Controls
We recruited 21 AD patients and 74 age-matched con-
trols. Seven AD eyes were excluded due to previously
established criteria (see Subjects and Methods) or because
TABLE 1. Optical Coherence Tomography Results in AD Patients and Controls
Characteristic AD, n5 21 Controls, n5 74 ANCOVA
Gender 11 M, 10 F 31 M, 43 F
Age 71.26 10.5 (51–84) 69.16 8.1 (52–85)
Disease duration, yr 5.26 2.5 (1–9)
MMSE 18.36 3.6 (13.5–26.1)
RNFL average, lm 88.86 8.4 (71–104) 95.86 12.3 (68–130) *p5 0.038,a f5 0.2196
RNFL-T, lm 67.26 10.4 (49–84) 69.36 10.5 (41–101) p5 0.762, f5 0.0316
RNFL-S, lm 104.46 13.4 (83–124) 117.16 17.6 (81–152) *p5 0.006,a f5 0.2949
RNFL-N, lm 66.66 13.9 (37–86) 74.36 15.3 (48–133) p5 0.081, f5 0.1759
RNFL-I, lm 116.56 15.5 (91–158) 122.46 18.1 (85–154) p5 0.303, f5 0.1102
aThe critical probability value for multiple comparisons (n5 4) corrected with Bonferroni method is 0.013.
AD5Alzheimer disease; ANCOVA5 analysis of covariance; f5Cohen f (detectable effect size with 80% power is 0.3075);
F5 female; I5 inferior; M5male; MMSE5Mini-Mental State Examination score; N5 nasal; RNFL5 retinal nerve fiber layer
thickness; S5 superior; T5 temporal.
La Morgia et al: mRGC Loss in AD
Month 2015 5
the OCT was technically unreliable. Overall, we included
21 and 74 eyes, randomly selected, for AD and age-
matched control cohorts, respectively. Three AD patients
had nonspecific visual complains (blurred vision),
whereas the remaining 18 AD patients did not present
visual symptoms. Demographic, clinical, and OCT find-
ings of AD patients and controls are summarized in
Table 1.
The average RNFL thickness was reduced in AD
patients compared with controls (p5 0.038; Fig 1A and
Table 1). Considering the 4 quadrants separately, the
superior quadrant was significantly thinner (p5 0.006)
in AD patients compared to controls (see Table 1). Aver-
age RNFL thickness was significantly correlated with age
(p< 0.001; see Fig 1B). The group3 age interaction
model failed to reveal a significant difference between
AD and controls for the RNFL thickness age-related
decline. RNFL thickness measurements did not signifi-
cantly correlate with MMSE score, age at onset, or dis-
ease duration. Moreover, we failed to demonstrate a
significant interaction between age and disease severity
on RNFL thickness measurements in AD.
Overall, AD patients demonstrated an age-related
loss of retinal fibers involving predominantly the superior
sector.
Actigraphic Evaluation of Rest–Activity Rhythm
Revealed Variable Degrees of Circadian Rhythm
Dysfunction and Sleep Efficiency Reduction in
AD Patients
Actigraphic monitoring of rest–activity rhythm was per-
formed in 16 AD patients and 10 controls, a subgroup
of the cohort investigated by OCT. Good compliance
was ensured insofar as bad hours represented only 0.6%
of the total recording time for AD patients and 0.3% for
controls (12 hours for AD and 4 hours for controls).
Clinical and demographic data of patients and controls
are summarized in Table 2. All but 4 AD patients were
on therapy for dementia consisting either of donepezil
(n5 4), rivastigmine (n5 2), memantine (n5 4), galant-
amine (n5 2), or both galantamine and rivastigmine
(n5 1).
There was a large variability of actigraphic profiles
among AD patients. Some AD patients resembled con-
trols, whereas others showed markedly disturbed circa-
dian rest–activity rhythms (Fig 2). Comparisons between
groups of nonparametric actigraphic measurements are
reported in Figure 2D–F and Table 3. RA was slightly
reduced in AD patients (0.66 0.13) compared to con-
trols (0.76 0.1), indicating a reduced variability of the
activity level across the 24-hour period; M10 was
FIGURE 1: Optical coherence tomography results in controls (CTRLS) and Alzheimer disease (AD) patients. (A) Average retinal
nerve fiber layer (RNFL) thickness results are reported for CTRLS and AD patients (*significant difference, p50.038). (B) Corre-
lations between average RNFL thickness and age in years is reported (p<0.001, R250.127).
TABLE 2. Demographic and Clinical Data of AD Patients and Controls Included for Actigraphic Studies
Subject Group Characteristic Min Max Mean SD
AD, n5 16 DISDUR, yr 1.00 9.00 4.8 2.5
MMSE 13.4 26.1 18.9 3.8
Age, yr 52 84 70.25 10.2
Controls, n5 10 Age, yr 54 80 65.8 7.5
AD5Alzheimer disease; DISDUR5 disease duration; Max5maximum; Min5minimum; MMSE5Mini-Mental State Exami-
nation score; SD5 standard deviation.
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FIGURE 2: Actigraphic results in controls and Alzheimer disease (AD) patients. (A–C) Examples of actigraphic profiles are shown
for a control (A), an AD patient with a profile resembling a control (B), and an AD patient with a severe disruption of the rest–
activity circadian rhythm (C). (D–F) Scatter plots of (D) interdaily stability (IS), (E) intradaily variability (IV), and (F) relative ampli-
tude (RA) for controls (gray circles) and AD patients (blue circles) are provided. Filled blue circles represent individual AD
patients with values >2 standard deviations from the mean of controls (“circadian-impaired” individuals).
TABLE 3. Actigraphic Results for AD Patients and Controls
Nonparametric measures AD, n5 16 Controls, n5 10 ANCOVA
IS 0.786 0.15 0.846 0.07 p5 0.126, f5 0.3389
IV 0.576 0.34 0.416 0.05 p5 0.198, f5 0.2827
RA 0.66 0.13 0.76 0.1 p5 0.041,a f5 0.4622
M10 258.96 36.07 282.596 15.25 p5 0.036,a f5 0.4749
L5 676 27.54 50.546 17.17 p5 0.122, f5 0.3425
AD5Alzheimer disease; ANCOVA5 analysis of covariance; f5Cohen f (detectable effect size with 80% power is 0.5749);
IS5 interdaily stability; IV5 intradaily variability; L55 least active 5-hour period; M105most active 10-hour period;
RA5 relative amplitude.
aThe critical probability value for multiple comparisons (n5 5) corrected with Bonferroni method is 0.01.
La Morgia et al: mRGC Loss in AD
Month 2015 7
258.96 36.07 in AD and 282.596 15.25 in controls,
indicating that AD patients were less active during the
wake period. L5 was 676 27.54 in AD and
50.546 17.17 in controls, indicating that AD patients
were more active during the night period. However, these
differences between AD and controls in terms of circa-
dian parameters were not significant after Bonferroni cor-
rection for multiple comparisons.
We also found a significant reduction of sleep effi-
ciency in AD patients (75.4%6 9.58%) compared with
controls (90.2%6 6.1%, p5 0.001). Patients and con-
trols did not significantly differ for subjective sleepiness
as evaluated by ESS, sleep quality as evaluated by PSQI,
and risk of sleep apnea as evaluated by Berlin
Questionnaire.
Furthermore, none of the actigraphic data assessing
rest–activity circadian rhythms significantly correlated
with clinical parameters (age, age at onset, disease dura-
tion, and MMSE score) or with OCT data.
Individual data for IS, IV, and RA of rest–activity
circadian rhythm results are shown in Figure 2D–F.
Overall, the graphic representation of single individuals
showed that AD patients demonstrated higher variability,
with scattered values, compared with controls, highlight-
ing that only a subgroup of them are “circadian
impaired.” The circadian impaired patients were defined
as cases with circadian values >2 standard deviations
(SD) from the mean of controls, as previously proposed.3
Overall, our in vivo studies documented that in
AD there is an age-dependent optic neuropathy and a
rest–activity circadian dysfunction affecting a subgroup
of patients. However, considering that mRGCs are only
1 to 2% of the total RGCs, their possible loss in the
context of reduced RNFL thickness, as a contributor to
circadian dysfunction, is overshadowed in the OCT
results. Thus, we directly investigated these cells in post-
mortem ocular specimens (retina and optic nerve; see
next section).
Postmortem Studies Confirmed the Age-
Related Loss of Axons and Revealed a Loss of
mRGCs in AD Patients
We investigated horizontal retinal sections stained with
an antibody targeting melanopsin to identify and count
immunoreactive mRGCs from 17 AD patients and 13
controls, adopting the same protocol used in a previous
study.36 Demographic, clinical, and neuropathological
information for controls are reported in Table 4.
Histological examination revealed the presence of
age-related macular degeneration in a 98-year-old AD
patient and proliferative diabetic retinopathy in a 70-
year-old AD case. Based on these comorbidities, we
excluded these 2 cases from the subsequent analysis.
Moreover, LM evaluation of optic nerve cross-sections
revealed a massive regional loss of axons compatible with
nonarteritic ischemic optic neuropathy in 1 AD case
(age5 86 years), which was also excluded from further
analysis. All the included AD cases (n5 14) showed pre-
served retinal anatomy. The main clinical premortem and
neuropathological features of the AD cases included are
summarized in Table 5.
The qualitative evaluation of the melanopsin-
stained AD retinal sections at the LM level showed that
the retinal layers were preserved as compared to age-
matched controls. We observed immunoreactive mRGCs
located in both the GCL and the INL, as previously
reported.47 Representative examples of immunoreactive
mRGCs and their dendrites in controls and AD patients
are provided in Figure 3A–H. In AD patients, we fre-
quently observed smaller somas and thinner dendrites. At
higher magnification, AD immunoreactive mRGCs often
displayed “patchy” melanopsin immunostaining in cell
bodies (see Fig 3B, D) and thinning of dendrites, which,
when seen between varicosities, produced a “beading”
effect to its appearance that we termed “focal attenu-
ations” (see Fig 3F, H).
Analysis of optic nerve cross-sections showed, in
some AD patients, evidence of optic neuropathy with
different degrees of axonal loss, corroborating previous
reports.9–11 Examples of optic nerve cross-sectional pro-
files from controls and AD cases with different degrees
of axonal loss are provided in Figure 3I–L. Interestingly,
the axonal loss predominantly affected the larger fibers in
the superior quadrants, and, to a lesser extent, the nasal
and inferior quadrants, whereas the temporal quadrants,
containing most of the smaller fibers, were largely spared
(see Fig 3K, L).
Overall, quantitative and statistical analyses for
axon and immunoreactive mRGC counts were performed
on 14 AD patients (age5 79.86 14.1 years; 7 males)
and 13 age-matched controls (age5 77.86 16.1 years; 9
males). Analysis of axonal counts showed a reduction in
AD patients compared to controls (Fig 4A), which did
not reach statistical significance (p5 0.346, f5 0.2929,
dES80%5 0.5630). Considering the different sectors
(superior, temporal, nasal, and inferior), although a
greater reduction was apparent for the superior quadrant
in AD, this was not significant compared to controls
(data not shown).
The immunoreactive mRGCs were equally distrib-
uted between the GCL and the INL in both AD patients
and controls, and there were no differences between
groups in terms of their distribution. The mRGC
density was significantly reduced in AD patients
ANNALS of Neurology
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(mean5 10.8246 2.079) compared with controls
(mean5 14.1536 3.149; p5 0.003, f5 0.6844,
dES80%5 0.5630; see Fig 4B). Melanopsin RGC number
was significantly correlated with age in controls
(p5 0.035; r520.517; see Fig 4C, upper panel) but not
in AD patients (p5 0.313; r5 0.143; see Fig 4C, lower
panel).
Axon number significantly correlated with age in
both controls (p5 0.001, r520.760) and AD patients
(p5 0.006, r520.646; see Fig 4C). Remarkably, in the
5th to 7th decades, the reduction of mRGC number in
AD patients occurred without a concomitant loss of reg-
ular RGCs, as reflected by axonal counts (see Fig 4C,
lower panel).
The relation between the normalized mRGC/RGC
ratio and age is shown in Figure 4D. We found a signifi-
cant principal effect of the group (p5 0.021), whereas
no significant effect of age (p5 0.082) or gender
(p5 0.718) was evident. A significant group3 age inter-
action (p5 0.026) indicated that the age-related variation
is different between AD and controls. This analysis high-
lights that mRGC loss in AD is evident also at an age
where AD patients have a normal RGC count (see
Fig. 4D).
Finally, there was no significant correlation between
mRGC density and axonal counts with either disease
duration, MMSE score, Braak score, or severity of AD
pathology, as assessed by B and C scores (see Subjects
and Methods).
In summary, we demonstrated mRGC loss in AD
compared with controls, which is evident before the
occurrence of the age-related axonal loss.
Analysis of Flat-Mounted Retinas Demonstrated
Morphological Abnormalities of mRGCs and
Reduction of Their Dendritic Size in AD
We also studied flat-mounted retinal preparations from 4
AD patients (mean age5 72.25 years) and 3 controls
TABLE 4. Summary of the Postmortem Control Cohort
ID Age at
Death, yr
Gender Time
at Death
Postmortem
Time
Cause of Death NP Report
C1 54 M 12:55 10:28 Anoxic brain injury secondary
to acute myocardial infarction
n.a.
C2 58 M 9:10 7:20 Upper gastrointestinal bleed
secondary to esophageal cancer
n.a.
C3 60 M 21:15 7:20 Metastatic lung cancer n.a.
C4 64 F 19:40 11:03 Cardiogenic shock secondary
to congestive heart failure
n.a.
C5 70 F 10:29 10:46 End-stage chronic obstructive
pulmonary disease
n.a.
C6 74 M 5:59 7:11 Ruptured brain aneurysm n.a.
C7 80 M 11:10 18:29 Respiratory failure secondary
to postoperative sequelae
n.a.
C8 80 M 16:30 13:12 Sudden respiratory failure
secondary to pneumonia
n.a.
C9 85 M 10:10 11:26 Gastrointestinal bleeding n.a.
C10 93 M 4:30 6:30 Subarachnoid hemorrhage Subarachnoid hemorrhage;
exclusion of AD diagnosis
C11 93 M 23:45 3:45 n.a. Amyloid angiopathy;
exclusion of AD diagnosis
C12 95 F 23:45 3:15 n.a. Normal brain (Braak score I);
amyloid angiopathy
in meningeal vessels
C13 105 F 5:30 6:00 Cardiopulmonary arrest Cerebrum infarct,
severe arteriosclerosis;
exclusion of AD diagnosis
C5 control; F5 female; M5male; n.a.5 not available; NP5neuropathological.
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(mean age5 75 years) from the same case series used in
postmortem studies. In controls, melanopsin was distrib-
uted, as previously described,47 along the membranes of
the soma, axons, and dendrites (Fig 5). Melanopsin
immunoreactive processes were found in 2 distinct den-
dritic mosaics—one with dendrites stratified in the inner
FIGURE 3.
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plexiform layer (IPL) close to the border of the GCL
and one with dendrites stratified in the outer IPL close
to the border of the INL. Inner stratifying cells had
somas exclusively located in the GCL, whereas outer
stratifying cell bodies were often displaced to the INL.
Melanopsin was found in the membrane of the dendritic
processes and in the relatively large “boutons en passant”
characteristic of the mRGCs. In AD patients, melanopsin
distribution was similar to controls, although several
areas showed sparse or lacking immunoreactivity prob-
ably due to insufficient immunostaining (decreased pene-
tration of primary or secondary antibody into the
vitreous body). Such areas were also found in controls.
However, in AD patients the dendritic processes looked
thinner and the boutons en passant were smaller or miss-
ing. Furthermore, melanopsin immunoreactivity was
patchy in the membrane of AD cells compared to what
seen in controls.
We analyzed a total of 18 cells from controls and
16 cells from AD patients in greater detail, measuring
the mean diameter of dendritic processes after a 3D
reconstruction of each cell using a specific software mod-
ule applied to the Z-stack of images (see Fig 5G–L).
This analysis demonstrated that the dendrites of AD
patients had a significantly smaller diameter compared to
controls (p5 0.003; see Fig 5M).
In summary, these findings confirm the qualitative
observations in the sagittal retinal sections and demon-
strate that AD patients also display abnormal mRGC
morphology.
Analysis of Flat-Mounted Retinas Revealed
Consistent Amyloid Deposition Affecting
mRGCs in AD
We further investigated whether the observed abnormal-
ities of immunoreactive mRGC and RGC degeneration
in AD patients were associated with retinal evidence of
Ab accumulation. Thus, we studied the superior hemi-
spheres flat-mounted retinas in 5 definite AD patients
(mean age5 73.4 years) and 5 age-matched controls
(mean age5 74.2 years) belonging to the original set
studied for mRGC counts, randomly including 1 subject
for each decade (Fig 6). We performed immunolabeling
with antihuman Ab monoclonal antibodies recognizing
diverse epitopes within the N0 and C0 terminus of the
Ab sequence (6E10 and 12F4). Representative micro-
scopic images from corresponding retinal locations dem-
onstrate the overall Ab burden in AD patients compared
with age-matched controls. Whereas no or minimal Ab-
immunoreactivity was detected in control retinas, a sub-
stantial Ab deposition was evident in all AD retinas. A
few sparse Ab deposits were also detected in the 95-year-
old control retina, distributed in a few retinal locations
(see Fig 6E and E1 inset, image at higher magnification).
This is comparable with the neuropathological report of
this individual indicating the presence of similar sparse
mature and immature plaques in the occipital cortex
(data not shown).
In AD retinas, Ab plaques were frequently found in
clusters, and higher magnification revealed the diverse
morphology of Ab depositions (see Fig 6). Intracellular
Ab immunoreactivity was abundant in the 51-, 64-, and
83-year-old AD patients. Extracellular abluminal Ab
deposits, with diffuse, immature and mature structures,
were the most prevalent in AD retinas. In all AD
patients we detected Ab deposits along the blood vessels
(perivascular), with some cases having extensive accumu-
lation. Similar to the brain, we found classical plaque
structures, displaying a central dense Ab core and radiat-
ing fibrillar arms, as well as “compact” plaques composed
of multiple dense-core globular Ab deposits with no
apparent radiating fibrils.
We further assessed the possible coexistence of Ab
deposition in and around immunoreactive mRGCs in
the same set of flat-mounted retinas from AD patients
(n5 5) and controls (n5 5; Fig 7). Our analysis indi-
cated absent Ab-immunoreactivity in and around intact
immunoreactive mRGCs in controls. On the contrary,
retinal Ab deposition in AD patients was consistently
FIGURE 3: Melanopsin retinal ganglion cells, their dendrites, and optic nerve cross-sections from controls and Alzheimer dis-
ease (AD) patients. Light micrographs of paraffin-embedded retinas, immunoperoxidase stained for melanopsin with diamino-
benzidine (brown color; A–H), and plastic-embedded optic nerve cross-sectional profiles, stained with paraphenylenediamine
(brown color) for myelin (I–L). (A) Control retina with a single melanopsin retinal ganglion cell (mRGC) in the ganglion cell layer
(GCL). Note homogeneous staining of cell body and dendrite (arrow). (B) AD retina with a single mRGC in the GCL. Note
patchy staining of melanopsin in the cell body (black arrow). A single dendrite can be seen with a focal attenuation (white
arrow) and varicosity (arrowhead). (C) Control retina with a single mRGC in the inner nuclear layer (INL). Note homogeneous
staining of the cell body (arrow). (D) AD retina with a single mRGC in the INL. Note patchy staining of melanopsin (arrow).
(E, G) Control retinas with a single immunostained dendrite (arrow) for melanopsin. Note caliber thickness. (F, H) AD retinas
with a single immunostained dendrite for melanopsin. Note thinning or focal attenuations (arrows) of dendrites between vari-
cosities (arrowheads). (I) Control optic nerve (1.18 million axons) with normal staining of axon bundles. The crossed lines delin-
eate an example of sectorial sampling in quadrants for axon counting. (J–L) Examples of AD optic nerves with mild (J; A3,
822,000 axons), moderate (K; A14, 706,000 axons), and severe (L; A6, 306,000 axons) axonal depletion. I5 inferior; INL5 inner
nuclear layer; IPL5 inner plexiform layer; N5nasal; S5 superior; T5 temporal. Scale bars: A–H, 10mm; I–L, 1mm.
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found inside immunoreactive mRGCs soma (arrowheads)
and extracellular/abluminal areas. The immunoreactive
mRGCs in AD retinas had abnormal morphology associ-
ated with intracellular and extracellular Ab. In AD reti-
nas, we found that Ab colocalized also in the neurites of
immunoreactive mRGCs.
Discussion
The present study demonstrates, for the first time, loss of
immunoreactive mRGCs in AD patients compared to
controls. The remaining mRGCs in AD patients dis-
played morphological abnormalities, in particular, a
reduction of dendritic diameter suggesting a possible
impairment of function. Additionally, we showed an age-
related loss of total RGCs, as reflected by axonal counts,
in optic nerves, confirmed in vivo by OCT studies.
Remarkably, the mRGC loss in AD occurred even with a
completely normal RGC count, suggesting that mRGCs
are specifically affected in AD. Furthermore, the AD
hallmark of amyloid pathology characterized postmortem
AD retinas, affecting specifically mRGCs. Finally, we
documented in vivo the presence of variable degrees of
rest–activity circadian dysfunction in mild-moderate AD.
Thus, we here propose that mRGC loss is a plausible
contributing factor to circadian dysfunction in AD.
The pattern of axonal loss documented by OCT
corroborated a similar trend in postmortem studies and
indicates a preferential involvement of the superior quad-
rant. This is consistent with previous OCT find-
ings.13,15–18,20 The preferential loss of fibers in the
superior quadrant is also compatible with the predomi-
nant inferior visual field defect documented in AD
patients.56 It is intriguing that the superior sector con-
tains the largest fibers of the optic nerve and previous
postmortem studies documented a preferential loss of the
larger axons, suggesting early involvement of the magno-
cellular RGCs in AD.11 These findings, including the
absence of large caliber fibers in the nerve fiber layer
spectra, have also been reported in glaucoma.57,58 Thus,
AD optic neuropathy may share some similarities with
glaucoma, which also has higher prevalence in AD
patients.59 Interestingly, this pattern of axonal loss also
fits with the demonstration of prominent Ab deposition
in the superior–temporal quadrant in flat-mounted reti-
nas (Koronyo et al: this study and unpublished results).
Our OCT findings and optic nerve axonal counts
confirmed the age-related decline of total RGCs, as
FIGURE 4: Melanopsin retinal ganglion cell (mRGC) density and axon number in controls and Alzheimer disease (AD) patients.
(A) Mean and standard deviation of axon counts in controls and AD. (B) Mean and standard deviation of mRGC density in con-
trols and AD patients (*significant difference, p50.003). (C) Correlation of axon count with age in years in controls (p50.001,
R250.577; orange circles, upper panel), correlation of mRGC number with age in years in controls (p50.035, R250.268; cyan
circles, upper panel), correlation of axon count with age in years in AD (p50.006, R250.417; orange circles, lower panel), and
correlation of mRGC number with age in years in AD (p50.313, R250.020; cyan circles, lower panel). (D) Correlations
between the standardized mRGC/RGC ratio and age in years are shown for controls (R250.012; upper panel) and AD
(R250.391; lower panel).
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reflected by loss of axons in the optic nerve, previously
documented by histological60 and OCT studies.61
The circadian rest–activity assessment of AD patients
revealed a wide variability for all the circadian parameters
analyzed. This could be due to the intrinsic nature of
pathology that produces variable severity of circadian
derangement in this disease, as already reported in other
case series.3 In our series of mild–moderate AD patients,
although we failed to detect a significant difference in
terms of circadian parameters (IS, IV, and RA) between
AD and controls, there was a subgroup of AD patients
with pathological circadian values (>2 SD from the mean
FIGURE 5: Flat-mounted retinas and dendritic process analysis in Alzheimer disease (AD) patients and controls (Con). (A–F) Mel-
anopsin immunoreactivity in control retinas (A, C, E) and in AD patients (B, D, F). At low magnification, melanopsin staining is
present in a subpopulation of ganglion cells and displaced ganglion cells forming a dendritic network. The dendritic network
of melanopsin processes in control retinas is characterized by long processes with a large “boutons en passant” (A, C, E). In
contrast, melanopsin retinal ganglion cells (mRGCs) in AD patients have an abnormal morphology in which dendritic processes
have a smaller diameter with a lack of “boutons en passant” (B, D, F). (G–L) Morphological analysis of control (G, I, K) and AD
mRGCs (H, J, L). Stacks of images of mRGCs were generated, and a 3-dimensional reconstruction was performed (see Subjects
and Methods), followed by analysis of the processes using the filament trace module in Imaris (Bitplane). In G, I, and K, 3 cells
from a control (green, purple, and yellow) and their dendritic processes are visualized. (G) The raw picture after deconvolution
and (I) after tracing of the processes are shown. (K) Only the traced cells identified by the program are shown. Similarly, in H,
J, and L, 3 mRGCs from AD an patient are shown. (M) The results of the total analysis of 18 cells from 3 controls (C3: 60 years
old, 6 cells; C5: 70 years old, 8 cells; C12: 95 years old, 4 cells) and 16 cells from 4 AD patients (A1: 51 years old, 5 cells; A2:
62 years old, 5 cells; A6: 80 years old, 3 cells; A13: 96 years old, 3 cells) are shown, demonstrating a significant reduction of
dendrite diameter in AD patients (*p50.003). Scale bars: A, B, 100mm; C, D, 50mm; E, F, 20 mm; G, I, K, 25mm; H, J, L, 24mm.
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FIGURE 6: Amyloid-b (Ab) deposition in the superior retinas of Alzheimer disease (AD) patients. Examination of Ab immunore-
activity in flat-mounted retinas from 5 definite AD cases (range551–98 years; A1: 51 years; A3: 64 years; A4: 71 years; A9: 83
years; A14: 98 years) and age-/gender-matched controls (range558–95 years; C2: 58 years; C4: 64 years; C6: 74 years; C8: 80
years; C12: 95 years) using anti-human Ab monoclonal antibodies and standard peroxidase-based techniques is shown. (A–J)
Representative micrographs from corresponding superior temporal quadrant locations in the retina exhibit no to minimal Ab
immunoreactivity in healthy control retinas (A–E) and substantial Ab burden in AD retinas (F–J; dark brown). Retinal Ab plaques
in AD patients are frequently found in clusters (F–J, left). Higher-magnification images demonstrate variable morphology of
extracellular Ab depositions (F1–J3), including immature plaques (H2, I3, J1, J2), classical mature plaques with central dense
Ab core and radiating fibrillar arms (F2, G2, H1, I2, J3), and compact plaques composed of multiple dense cores (H3, I1). Dif-
fuse plaques are typically found in postmortem retinas of AD patients (I3) but can occasionally be detected in aged healthy
control retina (E1). Intracellular Ab immunoreactivity is indicated with black arrows (F1, F2, G1, I). Furthermore, retinal Ab
deposits are also detected along blood vessels (I3, J3; blood vessel structures can be seen as transparent–lighter lane or tube
shapes containing erythrocytes). Scale bars520mm unless otherwise indicated.
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of controls). Furthermore, AD patients tended to be less
active during the day and more active during the night.
The circadian measures did not correlate with dementia
severity. These results are concordant with those reported
by others.3,62 The lack of significant differences compared
to controls for circadian parameters may be due to the
inclusion in our study of mild–moderate AD cases. By
contrast, most of the previous studies, documenting a
more severe circadian dysfunction in AD, included moder-
ate or severe patients,63–65 and did not correct the results
for multiple comparisons, whereas actigraphic studies
investigating mild–moderate AD patients failed to reveal
significant abnormalities.3,64 Differently, laboratory-based
polysomnography studies showed significantly reduced
sleep efficiency and slow wave sleep amount, even in the
mild cases, as in our case series.66,67 Selection of mild–
moderate cases was constrained by the need to have the
necessary compliance for reliable OCT studies. A previous
study by Hatfield and coauthors, in a 1-year follow-up of
mild–moderate AD patients, showed that the actigraphic
pattern did not deteriorate over time, even in the presence
of a significant decline of cognitive functions.3 This sug-
gests that cognitive and circadian abnormalities may have
different rates of progression, which could reflect different
pathophysiological mechanisms, as suggested in previous
studies.68 Moreover, the patients with the worst outcome
had a significantly lower stability of circadian parameters
at baseline evaluation.3 Thus, the presence of significant
circadian dysfunction in the early stages of disease may be
a predictive factor of poor outcome in AD patients.
FIGURE 7: Colocalization of amyloid-b (Ab) deposition and melanopsin retinal ganglion cells (mRGCs) in flat-mounted retinas of
Alzheimer disease (AD) patients. (A–F) Fluorescent immunohistochemistry analysis of flat-mounted retinas isolated from AD
patients (n55; A1: 51 years; A3: 64 years; A4: 71 years; A9: 83 years; A14: 98 years) and age-matched controls (n55; C2: 58
years; C4: 64 years; C6: 74 years; C8: 80 years; C12: 95 years) in different age groups (range551–98 years) colabeled with
anti-Ab (6E10) and antimelanopsin antibodies. (A) Representative micrograph from control individual demonstrates an intact
melanopsin-containing RGC having long dendrites without presence of Ab. (B, C) Representative micrographs from AD patients
demonstrating intracellular Ab deposition in mRGCs (arrowheads) as well as extracellular Ab (arrows). (D, E) The mRGCs exhib-
ited fewer cell processes. Abnormal morphology was frequently found in AD patients; mRGCs showed loss of dendritic arbori-
zation in the presence of intra- and extracellular Ab. (F) An example of an mRGC neurite from AD retina showing colocalization
with Ab (arrowheads). Scale bars520 mm unless otherwise indicated. DAPI540,6-diamidino-2-phenylindole.
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In our series, only a subgroup of AD patients had a
significant alteration of the circadian parameters. Mela-
nopsin RGCs represent only a small subgroup of RGCs
(about 1–2%), and it is difficult to infer from the OCT
results a direct contribution of these cells to circadian
dysfunction. Further investigation of mRGCs in these
patients was hampered by a lack of reliable approaches in
vivo. One possibility could have been the assessment of
mRGC-driven pupil response.69 However, the presence
of concomitant cholinergic dysfunction in AD may rep-
resent a confounding factor in the interpretation of pupil
response data.70 Moreover, different mRGC subtypes
may regulate pupil response and circadian photoentrain-
ment,31 and so the information obtained by pupil
recordings may not describe the contribution of mRGCs
to circadian rhythm regulation.
Therefore, to objectively and reliably evaluate the
presence of mRGC pathology in AD we looked at post-
mortem AD retinas. Our postmortem studies demon-
strated that, in addition to the total RGC loss, which
correlated with aging, there was mRGC loss in AD cases
that was present even in younger patients with a normal
RGC count. This suggests that, in AD, the mRGC sub-
population of RGCs may be more directly sensitive to
AD neuropathological mechanisms, in addition to the
more generalized age-related loss of total RGCs. This is
further supported by the observed morphological changes
of spared mRGCs, which were also abnormal, affecting
the dendrites and their arborization patterns, as well as
by their smaller cell bodies and patchy distribution of
the melanopsin photopigment within their cytoplasm
and in the membrane of the mRGC somata.
Furthermore, we documented in AD flat-mounted
retinas the presence of Ab deposition with classical amy-
loid plaques, as previously described.21 Interestingly, a
more recent study also documented phosphorylated-tau
deposition in AD human retinas.71 Importantly, Ab
deposits were frequently found inside and around
mRGCs. These mRGCs exhibited abnormal morphology
with substantial loss of axons and dendritic arborization.
The presence of amyloid pathology in AD retinas, specif-
ically in degenerating immunoreactive mRGCs, adds fur-
ther evidence that mRGC may be primarily affected by
Ab pathology in AD.
An alternative explanation for the specific loss of
mRGCs in AD may be retrograde axonal degeneration
deriving from primary pathology of the SCN. Neuronal
loss and classical AD neuropathology have been shown
in the SCN.2,5–7 A recent longitudinal study also demon-
strated a significant loss of neurons in the hypothalamic
ventrolateral preoptic nucleus correlated with sleep frag-
mentation, as documented by actigraphic recordings.72
Thus, the significant loss of mRGCs and the possible
dysfunction of remaining mRGCs, in conjunction with
other AD-related hypothalamic pathology, may all con-
tribute to the circadian rhythm and sleep abnormalities
in AD patients, and it may be difficult to distinguish the
individual contribution of the retinal and hypothalamic
damage.
The current study has some obvious limitations.
First, this is a cross-sectional study of 2 different cohorts
for in vivo and postmortem studies, where a direct corre-
lation between circadian dysfunction and mRGC loss
cannot be established. The 2 cohorts were enrolled with
different inclusion criteria, and we cannot exclude that
this may introduce a selection bias. Additionally, we rec-
ognize the relatively small sample size of the in vivo stud-
ies, the lack of an in vivo quantitative measure of mRGC
function, and the lack of access to postmortem hypo-
thalamic material. Furthermore, in our postmortem stud-
ies, we relied on immunoreactive mRGC counts using
melanopsin staining, and there is the remote possibility
that the AD degenerative process might reduce melanop-
sin expression. Finally, neuropathological data were not
available for all controls, but dementia was an exclusion
criterion for controls.
Overall, our study confirms the presence of optic
neuropathy and hallmarks of AD pathology in the retina
and shows, for the first time, the additional specific AD-
related pathology affecting mRGCs in AD. The mRGC
loss may provide the anatomical basis for a contributing
factor to the pathogenesis of circadian rhythm dysfunc-
tion in AD. The understanding of the mRGC–hypo-
thalamic contribution to circadian dysfunction in AD is
particularly important for the development of future
strategies aimed at counteracting circadian derangement
in AD patients, such as a specifically designed light ther-
apy.73 This is relevant considering that there is evidence
that circadian dysfunction is a strong predictor of
dementia in the elderly74 and robust circadian photoen-
trainment may prime longevity as well as quality of
life.75
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